Spiratisanin B exhibits significant antimicrobial activity, particularly against Gram-positive bacteria, making it a candidate for development in antibacterial therapies. It has shown potential in inhibiting biofilm formation, which is crucial in treating persistent infections associated with medical devices. Additionally, Spiratisanin B demonstrates anti-inflammatory properties by modulating key inflammatory pathways, suggesting possible use in inflammatory disease management. Its structural features also support investigation as a lead compound in antifungal drug research. Studies indicate moderate cytotoxicity against certain cancer cell lines, highlighting its relevance in anticancer agent exploration. Due to its natural origin and biological profile, it is being evaluated for use in pharmaceuticals and as a biochemical tool in mechanistic studies.